The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator an angiotensin converting enzyme inhibitor or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.